PTH-086 Comparison Of Clinical Presentations And Outcome Of Hepatocellular Carcinoma Between Hepatitis C And Nonalcoholic Fatty Liver Cirrhosis: A Single Centre Experience. (9th June 2014)

• Record Type: Journal Article
• Authors: Than, NN; Tehami, N; Hodson, J; Shetty, S
• Is Part Of: Gut. Volume 63(2014)Supplement 1
• Page Start: A247
• Page End: A248
• Publication Date: 2014-06-09
• Subjects: Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2014-307263.532
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Introduction: Hepatocellular carcinoma (HCC) is the most common primary liver tumour, and represents the third leading cause of cancer death worldwide. 1, 2 The most important risk factor is liver cirrhosis, mainly due to chronic infections such as hepatitis B or C .2 Increasing HCC cases are seen in nonalcoholic fatty liver disease (NAFLD). Methods: The aim of the study was to compare demographics, treatments and survival among hepatitis C virus (HCV/HCC) and NAFLD (NAFLD/HCC) cohort of patients. Data were collected from medical electronic case notes, imaging reports and HCC multidisciplinary meetings. Results: Among 292 patients, 212 patients (73%) had underlying HCV/HCC and 80 patients (27%) had NAFLD/HCC. The median age at diagnosis was significantly higher in NAFLD/HCC (p < 0.001). The majority (82%) were male. Body mass index (BMI) was significantly higher in NAFLD/HCC (p < 0.001). The majority were Caucasian (96%) in NAFLD/HCC, whilst the HCV/HCC cohort was significantly more ethnically diverse (p < 0.001). Diabetes mellitus was more common in NAFLD/HCC patients (p < 0.001). The median alpha fetoprotein level in HCV/HCC patients were 32.0 compared to 12.0 in NAFLD/HCC (p = 0.085). Patients with HCV/HCC were significantly more likely to be transplanted during the study period than NAFLD/HCC (30% vs. 15%, p = 0.010). Both transarterial chemoembolization (TACE) and percutaneous ethanol injection (PEI) were significantly more likely to be used as a single treatment in NAFLD patients, compared to HCV patients (p = 0.042, p = 0.021). Sorafenib was used as the only treatment in 6% of HCV/HCC and 3% of NAFLD/HCC cohorts (p = 0.364). Post transplant survival appeared to be worse in HCV-HCC patients compared to NAFLD/HCC, although it did not reach statistical significance (p = 0.081). Overall five year survival rates were similar between the two groups regardless of any treatment therapies (p = 0.424). Conclusion: Despite the NAFLD/HCC being older and with higher metabolic risk factors, a significant proportion could undergo active therapy. Furthermore, patients with NAFLD/HCC selected for transplantation seemed to have better long term outcomes, possibly due to stricter selection for transplantation as well as variations in tumour biology between the two groups. References: 1 Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013;47 Suppl:S2–6 2 Lu T, et al . P revention of hepatocellular carcinoma in chronic viral hepatitis B and C infection . World J Gastroenterol 2013;19(47):8887–8894 Disclosure of Interest: None Declared.